DelveInsight’s “Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epidermal growth factor receptor-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Epidermal growth factor receptor-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Epidermal growth factor receptor-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast
Some of the key facts of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report:
-
The Epidermal growth factor receptor-Non Small Cell Lung Cancer market size was valued ~USD 4,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In July 2024, Delta-Fly Pharma has begun enrolling participants in the Phase III clinical trial of DFP-14323 for treating non-small cell lung cancer (NSCLC). The trial aims to assess the combination of DFP-14323 with a 20mg daily dose of Afatinib, compared to a 40mg daily dose of Afatinib alone. It will enroll stage III/IV NSCLC patients in Japan who have uncommon EGFR mutations.
-
In April 2024, ORIC Pharmaceuticals, Inc. has completed the dose escalation phase of the Phase Ib trial for ORIC-114 in patients with advanced solid tumors featuring EGFR and HER2 exon 20 alterations or HER2 amplifications. Based on the results, ORIC has selected two provisional recommended Phase II doses (RP2D) of ORIC-114 at 80 mg and 120 mg QD, which are being further evaluated in three dose expansion cohorts for dose optimization and final RP2D determination. These cohorts have been initiated in patients with non-small cell lung cancer (NSCLC) having EGFR exon 20 (inhibitor-naïve), HER2 exon 20, or atypical EGFR mutations. Additionally, the company has launched an extension cohort for treating first-line, treatment-naïve EGFR exon 20 NSCLC patients.
-
In April 2024, Nuvalent, Inc. announced the unveiling of new preclinical data for its innovative HER2-selective inhibitor, NVL-330. The poster showcasing this data was presented at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10 in San Diego.
-
In 2023, the total number of incident cases of NSCLC across the 7MM was approximately 524,000, with expectations for this number to rise during the forecast period.
-
In 2023, the United States reported nearly 202,500 new cases of NSCLC.
-
In 2023, the total number of EGFR NSCLC cases in the EU4 and the UK was estimated to be around 31,200.
-
In 2023, the estimated number of EGFR Exon 20 insertion mutation cases in Japan was approximately 6,500.
-
Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
-
Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
-
The Epidermal growth factor receptor-NSCLC epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)
-
The Epidermal growth factor receptor-Non Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermal growth factor receptor-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the Epidermal growth factor receptor-Non Small Cell Lung Cancer market dynamics.
Epidermal growth factor receptor-Non Small Cell Lung Cancer Overview
EGFR-Non Small Cell Lung Cancer (EGFR-NSCLC) is a subtype of non-small cell lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. These mutations lead to abnormal cell growth and division. EGFR-NSCLC is more common in non-smokers, women, and people of East Asian descent.
Get a Free sample for the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report –
Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Segmentation:
The Epidermal growth factor receptor-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of EGFR-Non Small Cell Lung Cancer
-
Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity
-
Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer
-
Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer
Download the report to understand which factors are driving Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast
Epidermal growth factor receptor-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermal growth factor receptor-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Epidermal growth factor receptor-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epidermal growth factor receptor-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies and Key Companies
-
TAGRISSO: AstraZeneca
-
RYBREVANT: J&J Innovative Medicine
-
Aumolertinib: Hansoh Pharmaceutical
-
Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical
-
Telisotuzumab Vedotin(Teliso-V): Abbvie
-
Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)
-
Nazartinib (EGF816): Novartis
-
Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo
Discover more about therapies set to grab major Epidermal growth factor receptor-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market
Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers
-
Increasing Use of Biomarker Testing
-
Increase in the Mutation Specific Trials Activity and Approval
-
Increasing Incidence of NSCLC
-
Rich Pipeline and label expansion of approved therapies
Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers
-
Cost-Effectiveness of Therapies
-
Small Patient Populations for Specific Subsets of NSCLC
-
Generic or Biosimilar Erosion
Scope of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others
-
Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
-
Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapeutic Assessment: Epidermal growth factor receptor-Non Small Cell Lung Cancer current marketed and Epidermal growth factor receptor-Non Small Cell Lung Cancer emerging therapies
-
Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Dynamics: Epidermal growth factor receptor-Non Small Cell Lung Cancer market drivers and Epidermal growth factor receptor-Non Small Cell Lung Cancer market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement
To know more about Epidermal growth factor receptor-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-NSCLC Clinical Trials and Therapeutic Assessment
Table of Contents
1. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for Epidermal growth factor receptor-Non Small Cell Lung Cancer
3. SWOT analysis of Epidermal growth factor receptor-Non Small Cell Lung Cancer
4. Epidermal growth factor receptor-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Overview at a Glance
6. Epidermal growth factor receptor-Non Small Cell Lung Cancer Disease Background and Overview
7. Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Epidermal growth factor receptor-Non Small Cell Lung Cancer
9. Epidermal growth factor receptor-Non Small Cell Lung Cancer Current Treatment and Medical Practices
10. Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs
11. Epidermal growth factor receptor-Non Small Cell Lung Cancer Emerging Therapies
12. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Outlook
13. Country-Wise Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Analysis (2020–2034)
14. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers
16. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers
17. Epidermal growth factor receptor-Non Small Cell Lung Cancer Appendix
18. Epidermal growth factor receptor-Non Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/